Metabolic changes over the course of aging in a mouse model of tau deposition

Aurélie Joly-Amado a,b,*, Karisa S. Serraneau a,b, Milene Brownlow a,b, Caralina Marín de Evsikova c, John R. Speakman d, Marcia N. Gordon a,b, Dave Morgan a,b

a Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA
b Byrd Alzheimer’s Institute, University of South Florida, Tampa, FL, USA
c Molecular Medicine, University of South Florida, Tampa, FL, USA
d State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Chaoyang, Beijing, China

A R T I C L E   I N F O

Article history:
Received 23 November 2015
Received in revised form 1 April 2016
Accepted 18 April 2016
Available online 25 April 2016

Keywords:
Alzheimer’s disease
Tauopathy
Tau protein
Metabolism
Basal metabolic rate
Locomotor activity
Energy expenditure
Tg4510
Mice
Transgenic
Body weight gain
Food intake

A B S T R A C T

Weight loss and food intake disturbances that often precede cognitive decline and diagnosis have been extensively reported in Alzheimer’s disease patients. Previously, we observed that transgenic mice over-expressing tau seemed to eat more food yet weigh less than nontransgenic littermates. Thus, the present longitudinal study measured the time course of changes in metabolic state over the lifespan of the tau depositing Tg4510 mouse model of tau deposition. Although body weight was comparable to nontransgenic littermates at 2 months of age, Tg4510 mice weighed less at older ages. This was accompanied by the accumulation of tau pathology and by dramatically increased activity in all phases of the 24-hour cycle. Resting metabolic rate was also increased at 7 months of age. At 12 months near the end of the Tg4510 lifespan, there was a wasting phase, with a considerable decrease of resting metabolic rate, although hyperactivity was maintained. These diverse changes in metabolism in a mouse model of tau deposition are discussed in the context of known changes in energy metabolism in Alzheimer’s disease.

© 2016 Elsevier Inc. All rights reserved.

1. Introduction

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the accumulation of beta amyloid (Aβ), which forms extracellular plaques, neurofibrillary tangles composed of tau protein, and cognitive declines, such as episodic memory disorder, visuospatial impairment, and deteriorating executive function (Baudic et al., 2006). In addition, AD is characterized by noncognitive symptomatology. Weight loss is a noncognitive symptom that is commonly reported in AD patients and was described by Alois Alzheimer in his original report from 1906 (Gillette et al., 2007; Tamura et al., 2007). Many epidemiological studies have since confirmed this initial observation, and it is now recognized as a clinical feature of AD (McKhann et al., 1984), impacting 20%–45% of the patients (Gillette-Guyonnet et al., 2000, 2005; Guerin et al., 2005a, 2005b; Vellas et al., 2005). Weight loss in demented patients is associated with adverse outcomes, such as an accelerated progression of AD, a higher rate of institutionalization (Andrieu et al., 2001) and increased mortality (Faxen-Irving et al., 2005; Gambassi et al., 1999; White et al., 1998). Although dementia-associated weight loss often begins before the onset of the clinical syndrome and accelerates by the time of diagnosis, it is unclear if it is a cause or a consequence of AD pathology (Inelmen et al., 2010).

Overall, to decrease body mass, energy intake must be lower than energy expenditure (Morton et al., 2006), although food intake in people with AD is usually normal or sometimes even increased (Burns et al., 1989; Keene and Hope, 1997; Niskanen et al., 1993;
Spindler et al., 1996). Indeed, paradoxical overeating concomitant with weight loss has been observed in patients with AD (Wolf-Klein et al., 1992) and in frontotemporal dementia (FTD), another tauopathy (Bozeat et al., 2000; Piquet, 2011; Snowden et al., 2001). The observation of significant weight loss in the absence of decreased food intake suggests the possibility of a hypermetabolic state in AD (Vloeberghs et al., 2008; Wolf-Klein et al., 1992). Hypermetabolism is the physiological state of increased metabolic activity, which is typically characterized by an elevated basal metabolic rate. It is uncertain whether abnormalities in metabolism exist in AD patients because no consistent changes (either increase or reduction) in basal metabolism have been reported (Donaldson et al., 1996; Niskanen et al., 1993).

Nevertheless, many factors contribute to daily metabolism. High-energy expenditure may be caused, for example, by increased physical activity levels such as wandering or excessive pacing, which are recognized symptoms in AD (Devanand et al., 1992, 1997; Lopez et al., 1999). Circadian behaviors are also altered in AD patients with increased activity during evening hours, “sundowning” (Scarmeas et al., 2007), sleep fragmentation at night, and a tendency to sleep during daytime (Ancoli-Israel et al., 1994).

These characteristics are consistent with observations made previously in different mouse models of AD pathology. Indeed, lower body weight and increased feeding behavior have been described in different models of amyloid deposition (Morgan and Gordon, 2008; Pugh et al., 2007; Vloeberghs et al., 2008). Specifically, Tg2576 amyloid precursor protein mice exhibit lower weight without alterations in feeding behavior (Brownlow et al., 2013; Ishii et al., 2014), but associated with increased energy expenditure (Ishii et al., 2014) or increased activity in open field tests (Brownlow et al., 2013). In addition, 3xTgAD mice display increased body weight at 3 and 6 months of age (Adebakin et al., 2012; Knight et al., 2012) with increased appetite starting at 2 months (Knight et al., 2012) that continues up to 12 months, although body weight is decreased at 12 months compared with nontransgenic mice due to an increase in metabolism (Knight et al., 2012). A slight increase in activity during the day was also reported in these mice at 10 months of age (Knight et al., 2013), although a different cohort showed no difference in body weight and hypoactivity in open field tests at 14–20 months of age (Filali et al., 2012). Abnormalities in circadian rhythmicity were also observed in these mice, which may explain these discrepancies in the subsequent cohorts (Sterniczuk et al., 2010).

Hyperactivity and increased agitation have been reported in mouse models of tau deposition such as THY-22 (P301S mutation under a Thy1.2 promoter) and Tg4510 (Jul et al., 2015; Van der Jeugd et al., 2013) together with a decrease in body weight (Brownlow et al., 2013, 2014; Leboucher et al., 2013). Despite all of these observations of altered body weight in mouse models of AD, there is no current report of energy balance variations in a mouse model of tauopathy to our knowledge.

Therefore, the aim of this study was to examine longitudinal changes in body weight, food intake, and energy expenditure in addition to locomotor activity in a mouse model of tau deposition, Tg4510 mice. These mice develop progressive pathology with histologically discernible tau deposits similar to that found in AD patients at 3 months of age, leading to neuronal loss, and atrophy by 6 months of age (Dickey et al., 2009; Santacruz et al., 2005).

2. Methods

2.1. Animals and experimental design

All animal testing procedures were approved by the Institutional Animal Care and Use Committee of the University of South Florida and were performed in accordance with the eighth edition “Guide for the Care and Use of Laboratory Animals,” published by the National Academy of Science, the National Academies Press, Washington, DC (2011).

Parental mutant tau and tetracycline-controlled transactivator protein (tTA) mouse lines were maintained separately and bred to produce Tg4510 mice as described previously (Santacruz et al., 2005). Because the 2 transgenes segregate independently, offspring can carry neither transgene (nontransgenic), a single transgene alone (tau only or tTA only), or both transgenes (Tg4510). The Tg4510 mouse expresses tau with a P301L mutation, which is associated with an autosomal dominantly inherited dementia referred to as FTD and parkinsonism linked to chromosome 17 (FTDP-17; Hutton et al., 1998). This model differs from most other tau transgenic mice, in that most of tau pathology and neurodegeneration is found in the forebrain rather than the spinal cord. This neuroanatomical specificity is caused by tetransactivator being regulated by the CaM kinase II promoter, resulting in expression predominantly in forebrain neurons. These mice develop progressive pathology with histologically discernible tau deposits consistently observed at 3 months, progressing through a series of conformational, and hyperphosphorylated forms analogous to that found in AD patients, leading to neuronal loss and atrophy by 6 months of age (Dickey et al., 2009; Santacruz et al., 2005). Mice were housed individually and maintained on a 12-hour light/dark cycle. Food (NIH-31, Harlan) and water were given ad libitum. Mice in the University of South Florida (USF) Tg4510 colony were weighed routinely. Weight data collected from 2594 mice were binned into monthly averages for each genotype.

For the longitudinal study in metabolism cages, a group of 2-month-old Tg4510 transgenic mice (n = 6) and control nontransgenic littermates Friend Virus B NIH Jackson (FVB/NJ)/129S F1 hybrid background, n = 6 with an equal number of males and females were used. The same group of animals was tested again at both 7 and 12 months of age. Tet (tTA) only control mice were tested in metabolic cages at the 7-month-old time point (n = 4). Additional groups of mice were euthanized at the same time points (2 month old n = 5, 7 month old n = 10, and 12-month old n = 4) for histology, biochemistry, and tissue dissection.

2.2. Energy expenditure and locomotor activity analysis with indirect calorimetry

Mice were analyzed for whole body energy expenditure (kcal/h), oxygen consumption, and carbon dioxide production, respiratory exchange rate (VCO2/V02), food intake (Kcal) and locomotor activity (counts/h) using calorimetric cages (Phenomaster, TSE Systems, Chesterfield, MO, USA) with bedding, food, and water measurements, as previously described (Joly-Amado et al., 2012). Composition of gases was compared to a reference empty cage, and whole animal energy expenditure was calculated according to the Weir equation for respiratory gas exchange measurements (Weir, 1949).

Each cage was equipped with an array of highly sensitive feeding and drinking sensors for automated online measurement and locomotion monitored with an infrared light beam—based system. Night over day activity ratio was calculated by dividing the total activity at night by the total activity during the day for each mouse.

Mice were individually housed with free access to food and water ad libitum with lights on from 6 AM to 6 PM and an ambient temperature of 22°C ± 1°C. All animals were acclimated to the metabolism cages for 24 hours before experimental measurements were recorded. Data analysis was performed using O2 consumption, CO2 production (expressed in ml/h), and energy expenditure (kcal/h). Data were analyzed using ANCOVA as recommended by (Tschop et al., 2012). Resting metabolic rate (RMR) was estimated by using general linear mixed effects modeling (GLM-MM, SPSS software,
version 22) with intercepts of oxygen consumption and activity plots when the activity value = 0.

2.3. Apparent energy absorption efficiency and food efficiency

Measurements of energy intake were made at 2, 7, and 12 months. In the morning, bedding was changed and a weighed portion of food was added to the hopper. Twenty-four hours later, the food remaining in the hopper was reweighed and feces were removed from the cage, dried to a constant mass at 60 °C for 48 hours and weighed again. The gross energy content of feces was measured by bomb calorimetry. We calculated the daily energy intake of each mouse by calculating food consumption (g/d) from food removed from hopper (g/d) — uneaten food from the cage floor (g/d). The energy lost through defecation (kcal/d) was calculated from dry fecal production (g/d) × faecal energy content (kcal/g of dry mass). The apparent energy absorption efficiency (AEAE) was calculated as the percentage of gross energy intake that was digested of the daily energy intake (Krol et al., 2007). Food efficiency was calculated as described in (Joly-Amado et al., 2012). Briefly, the body weight gain over a period of 6 months was normalized to the amount of calories ingested over the same period (between 4 and 10 months of age).

2.4. Feces analysis

To measure the energy content of each biological sample, a sample was combusted with an Isoperibol Calorimeter 6200 instrument with a model 1108 oxygen bomb (Parr Instrument Co, Moline, IL, USA) following manufacturer instructions. Briefly, after preparation, the pellet was weighed and placed in a model 1108 oxygen bomb with contact to a 10-cm fuse wire connected to a 2901EB ignition unit (Parr Instrument Co). The bomb was placed in a bomb cylinder surrounded by 2000-mL distilled water. The heat produced at the combustion of the pellet was sensed as a rise of water temperature. Bombs were calibrated using benzoic acid before each use. To give the energy equivalent (W) per change in water temperature (ΔT), amount of benzoic acid standards with a temperature rise equivalent to the samples tested were conducted every 10 burns. The energy content of the pellet (ES) was calculated as follows: $E_s = W \times \Delta T / \text{the weight of}$
the pellet. The total number of calories in the sample was calculated on the basis of weight of the sample.

2.5. Tissue collection

Three different groups of transgenic mice and age-matched nontransgenic littermates were euthanized at 2, 7, and 12 months of age with a solution containing pentobarbital and phenytoin, then transcardially perfused with 25 mL of 0.9% normal saline solution. Mice were placed on an isothermal pad during perfusion to minimize generation of artefactual tau phosphorylation, which has been reported to result from lowered body temperature caused by the euthanizing solution (Maurin et al., 2014; Planel et al., 2007). Brains were collected immediately after perfusion. One hemisphere was dissected and frozen for Western analysis and the second hemisphere was immersion fixed in 4% phosphate-buffered paraformaldehyde for 24 hours. The fixed hemispheres were cryoprotected in successive incubations of 10%, 20%, and 30% sucrose solutions for 24 hours each. Subsequently, brains were frozen on a cold stage and sectioned in the horizontal or coronal plane (25-μm thickness) on a sliding microtome and stored in Dulbecco’s phosphate-buffered saline with 10-mM sodium azide solution at 4°C. Brown adipose tissue, white adipose tissue (specifically perirenal and subcutaneous depots), and muscle (as extensor digitorum longus muscle, tibialis, and soleus) were dissected and weighed. For white adipose tissue, data are presented as the sum of both perirenal and subcutaneous depots. For muscle tissue, data are presented as the sum of extensor digitorum longus muscle, tibialis, and soleus. Blood was collected from intracardiac puncture using ethylenediaminetetraacetic acid and then centrifuged at 1000g for 15 minutes at 4°C for plasma collection.

Fig. 2. Body weight and energy intake. Time course of body weight in Tg4510 mice versus nontransgenic littermates (Ntg) at 2 (black bars), 7 (white bars), and 12 months of age (shaded bars; A). Evolution of body weight in all littermates: nontransgenic, tau only (Tau), tet only (tTA), and tau + tet (Tg4510) over the course of aging (B; data extracted from the mouse colony database). Twenty-four-hour food intake raw (C) or normalized to body weight (D), food intake efficiency (E) and apparent energy absorption efficiency (F), in Tg4510 mice versus nontransgenic littermates at 2 (black bars), 7 (white bars), and 12 months of age (shaded bars). Food intake efficiency was calculated as mg of body weight gain/kcal consumed over a period of 6 months (between 4 and 10 months of age). Statistical analysis was performed using 2-way ANOVA. Data are presented as mean ± standard error of the mean ***p < 0.001, **p < 0.01, *p < 0.05.
2.6. Histopathology

Stereological principles were used to select the sections stained for each marker. Immunohistochemical procedural methods were described (Gordon et al., 2002). Sections from all animals were placed in a multistain sampling tray and endogenous peroxidase was blocked (10% methanol, 3% H2O2 in phosphate-buffered saline (PBS), 10-mM NaPO4, 154 NaCl, pH 7.4, PBS; 30 minutes). Tissue samples were permeabilized with 0.2% lysine, 1% Triton X-100 in PBS solution, and incubated overnight in anti-tau phosphorylated at Ser396 (rabbit polyclonal, Anaspec). Sections were washed in PBS and then incubated in corresponding biotinylated secondary antibody (Vector Laboratories, Burlingame, CA, USA). The tissue was again washed after 2 hours and incubated with Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) for enzyme conjugation. Finally, sections were stained using 0.05% dianisobenzidine, 0.5% nickel ammonium sulfate, and 0.03% H2O2. Tissue sections were mounted onto slides, dehydrated, cover slipped and scanned for analysis using slide scanner Axio Scan Z1 (Zeiss Inc). Hippocampal and cortical volume (expressed in mm3) was calculated by measuring regional area of 8 sections (25-μm thickness) using Zeiss software (Zeiss Inc) and applying the formula: V = ΣA × T, where ΣA = sum of the regional areas on the sections analyzed, and T = section interval × T (section thickness after tissue processing). Stained sections were imaged using Zeiss digital scanning microscope and Image Analysis Software.

2.7. Western blotting and ELISA

Tissues for Western blot analysis were prepared as previously described (Brownlow et al., 2014). Briefly, brown adipose tissue was quickly minced in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitor cocktail (Sigma Aldrich) and phosphatase inhibitor cocktails I and II (Sigma Aldrich) and centrifuged at 14,000 rpm for 30 minutes. The supernatant was collected, and protein concentrations were determined by the BCA protein assay kit (Pierce, Rockford, IL, USA). Equal amounts of proteins (40 μg/well) were loaded in each well of a 4%–12% SDS-PAGE gel and transferred to a 0.2-μm pore size nitrocellulose membrane and immunoblotted with antiamouse uncoupling protein 1 (UCP-1; Alpha Diagnostics, TX, USA), antimouse Peroxisome proliferator-activated receptor γ coactivator 1-α (PGC1-α; Abcam, Cambridge, MA, USA) and antiamouse β-actin (Sigma Aldrich) at 1:1000-fold dilution. Fluorescently tagged secondary antibodies (IRDye 800CW, LI-COR Biosciences) were used at a dilution of 1:10,000. Band intensities were quantified by densitometric analysis and normalized to the band intensity of β-actin using the Odyssey imaging system (LI-COR Biosciences). Measurement of plasma leptin concentration was performed using a mouse leptin ELISA kit (Life Technologies, CA, USA) according to the manufacturer’s instructions.

2.8. Statistical methods

Data were analyzed by 2-way ANOVA or repeated measures ANOVA followed by Fisher’s protected least significant difference post hoc tests (Statview) or ANCOVA (SPSS, version 22). In all tests, a p-value < 0.05 was considered significant. All data are presented as mean values ± standard error of the mean unless specified otherwise.

3. Results

3.1. Age-related pathology in Tg4510 mice

Consistent with previous studies (Santacruz et al., 2005), no hyperphosphorylated tau (pser396) was detected in 2-month-old Tg4510 mice (Fig. 1A, E, and I) or in nontransgenic littermates (data not shown). At 7 months of age, pser396 was detected in the forebrain (Fig. 1B), more specifically in neurons in both hippocampus (Fig. 1F) and cortex (Fig. 1J). Pser396 staining spread to the parenchyma at 12 months of age (Fig. 1C, G, and K). The increased expression of phosphorylated tau was accompanied by decreased brain weight in Tg4510 mice at both 7 and 12 months (Fig. 1D). There was no genotype difference in brain weight at 2 months. In addition, decreased hippocampal volume (Fig. 1H) and decreased cortex volume (Fig. 1L) were observed in Tg4510 mice at 7 and 12 months of age compared with nontransgenic littermates, but not at 2 months (data not shown). In addition, in Tg4510 mice, hippocampal and cortical volume were significantly reduced between 7 months and 12 months (Fig. 1H and I), reflecting the worsening of pathology with aging.

3.2. Age-related body weight loss in Tg4510 mice was independent of food intake

No differences were observed in body weight between 2 months Tg4510 mice and nontransgenic littermates. However, as mice in the longitudinal study aged, body weight was significantly lower at 7 and 12 months in Tg4510 mice compared with nontransgenic littermates (Fig. 2A). These age-related differences in body weight were confirmed in our collection of body weight information from more than 250 mice derived from our colony over the past 8 years. ANOVA revealed main effects of age and genotype as expected (Fig. 2B). Post hoc analysis at 1 month of age revealed a significant difference between all genotypes, with tau only littermates displaying a slight but significant decrease in body weight compared with nontransgenic littermates (20.5 g ± 0.13 vs. 20.9 ± 0.14, n = 608 and 547, respectively). Tg4510 (tau + tet) and tet only mice displayed a significant increase in body weight compared with nontransgenic littermates (21.8 ± 0.17 and 23.4 ± 0.16 vs. 20.9 ± 0.14, n = 383, 474, and 547, respectively). However, body weight was not different between tau or Tg4510 mice compared with nontransgenic littermates at 2 months of age, although tet only mice (tTA) were still significantly heavier. At 3 months of age, Tg4510 mice started to have lower body weight compared with all other genotypes, and that difference grew larger over the ensuing year. Tau only mice body weights remained similar to nontransgenic littermates over the course of aging after 2 months of age. Tet only mice body weights remained significantly higher than all other genotypes until 9 months of age. Together, these data show that the reduced body weight in the Tg4510 mice is not due to weight differences caused by one of the background transgenes (tTA in tet only or tau in tau only) but most likely due to the increased expression of tau and accumulation of tau deposits in the Tg4510 mice.

No difference was observed in daily food intake (Fig. 2C) or food intake normalized to body weight (Fig. 2D) in Tg4510 mice compared with nontransgenic littermates at 2 months and 12 months. Remarkably, 7-month-old Tg4510 mice displayed higher food intake than nontransgenic littermates, indicating that reductions in food intake could not account for the lower body weight (Fig. 2C and D). However, food intake efficiency, that is, body weight gain normalized to the amount of calories ingested over a period of 6 months (from 4 to 10 months of age) was dramatically decreased in Tg4510 mice compared with nontransgenic littermates (Fig. 2E). The AEAE, derived from calories remaining in feces, was not different among the different ages between Tg4510 and nontransgenic littermates. Thus, body weight loss or reduction in food intake efficiency was not due to defective energy absorption (Fig. 2F).

3.3. Decrease in white but not brown fat depots in Tg4510 mice

Consistent with the decrease in body weight, 7- and 12-month-old Tg4510 mice showed a dramatic decrease in the size of the
white fat pads compared with age-matched, nontransgenic mice (Fig. 3A). Indeed, although white adipose tissue content increased significantly over the course of aging in nontransgenic littermates, it remained low in Tg4510 mice, with no significant increase with aging. Measurement of leptin concentration in plasma matched the variations observed in white adipose tissue content in both nontransgenic and Tg4510 mice (Fig. 3B). At 2 months of age, there were no differences in the amount of white fat pads or plasma leptin level between Tg4510 and nontransgenic littermates (Fig. 3A and B).

There were no differences between age-matched Tg4510 and nontransgenic littermates in muscle mass (data not shown) or in brown adipose tissue weight (Fig. 3C), although there were main effects of aging. Similarly, basal levels of UCP-1 (Fig. 3D and F) and PGC1-α (Fig. 3E and F) were similar in age-matched Tg4510 and nontransgenic littermates in brown adipose tissue when assessed by Western blot.

3.4. A progressive hyperactivity phenotype developed in Tg4510 mice

At 2 months of age, there were no significant differences in average activity levels or in the timing or amplitude of daily activity rhythms between transgenic and nontransgenic littermates (Fig. 4A). The peak in activity observed at the beginning of the dark phase was observed at the same time in Tg4510 mice and nontransgenic littermates. Even though the amplitude of the peak appeared consistently higher in transgenic mice, the difference was not statistically significant (Fig. 4A). There was no genotype

---

**Fig. 3.** Adipose tissue analysis. The time course of changes in white adipose tissue weight (A), plasma levels of leptin (B), brown adipose tissue weight (C), and levels of UCP-1 (D, F) and PGC1-α (E,F) are presented. UCP-1 and PGC-1α in brown adipose tissue was assessed by Western blot analysis (F), and band intensity was normalized to actin in transgenic Tg4510 mice and nontransgenic littermates (Ntg) at 2 (black bars), 7 (white bars), and 12 months of age (shaded bars). Statistical analysis was performed using 2-way ANOVA. Data are presented as mean ± standard error of the mean "***p < 0.001, **p < 0.01, *p < 0.05."
difference of activity partitioning during the day and at night at 2 months (Fig. 4D). Prominently, at 7 months, a significant increase was observed in the amplitude of daily activity profiles for Tg4510 mice compared with nontransgenic littermates (Fig. 4B; note change in Y axis scaling). The genotype difference was greater at night than during the day, with Tg4510 mice reaching a 2-fold increase during the day and nearly 7-fold at night. At this age, we also included tTA littermate mice in the metabolic cages. As expected, no difference in locomotor activity was observed in tTA mice compared with nontransgenic animals (Fig. 4B). At 12 months, the genotype differences in activity were even greater than at 7 months during both day and night reaching a 4.5-fold increase in Tg4510 mice during the day and an 8-fold increase at night (Fig. 4C). The genotype difference in the ratio of night activity over day activity is illustrated in Fig. 4D. Interestingly, night over day ratio activity decreased with aging in nontransgenic mice, but Tg4510 mice displayed an increase in this ratio, largely due to increased activity in the dark phase (rather than decreased activity during the light phase; Fig. 4D). This difference suggests transgenic mice are still sensitive to circadian cues because they are more active at night than during the day.

3.5. Changes in metabolism and fuel utilization

Total daily energy expenditure (DEE) was significantly lower in 2-month-old Tg4510 mice compared with nontransgenic mice (Fig. 5A). Although 24-hour DEE was not significantly different in 7-month-old Tg4510 mice compared with nontransgenic and tTA littermates, Tg4510 mice exhibited increased energy expenditure at night (Fig. 5B). Total 24-hour DEE was not significantly different in 12-month-old Tg4510 mice compared with nontransgenic littermates, although we observed significantly lower energy expenditure during the day (Fig. 5C). RMR was calculated using values of oxygen consumption when activity was null. RMR was lower in 2-month-old Tg4510 mice compared with controls, whereas it was higher than both nontransgenic and tTA littermates at 7 month old, suggesting a switch in metabolic efficiency (Fig. 5D). Later in life, resting metabolism was lower in Tg4510 mice again (Fig. 5D).

The 24-hour respiratory exchange rate (RER) was not significantly different at 2 and 7 months between Tg4510 mice and nontransgenic or tTA littermates. However, 12-month-old Tg4510 mice displayed a significantly lower RER compared with nontransgenic mice, 0.75 versus 0.81, respectively (Fig. 5E), suggesting a preference toward fat as a metabolic fuel (Longo et al., 2010). Circadian analysis of RER showed that 12-month-old Tg4510 mice stayed around 0.75 in both night and day, whereas nontransgenic mice displayed circadian changes in RER with a higher RER at night versus the day, reflecting the consumption and use of dietary carbohydrates as the main source of metabolic fuel during the night (data not shown). Overall, lower RER suggests Tg4510 mice are biased toward fat as the primary metabolic fuel, whereas nontransgenic littermates would be on a mixed substrate oxidation, which parallels our observations in fat pad size.

3.6. Tau pathology in hypothalamus over the course of aging in Tg4510 mice

Immunostaining against hyperphosphorylated tau (pser396) in coronal sections revealed the presence of pathology in the hypothalamus of Tg4510 mice at 7 (Fig. 6B) and 12 months of age (Fig. 6D),
which was not present in nontransgenic littermates (Fig. 6A and C). No staining was detected in 2-month-old mice (see Fig. 1A).

All data are summarized in Table 1.

4. Discussion

In this study, we showed metabolic disturbances in a mouse model of tau deposition that resembled some noncognitive symptomatology reported in both AD patients and mice with amyloid deposition. Our results indicated that increased tau pathology in Tg4510 mice was accompanied by lower body weight and associated with reduced fat depot size. This body weight loss was not caused by a decrease in food intake or energy absorption but was accompanied by a significant decrease in food efficiency (i.e., body weight gain normalized to calorie intake) in Tg4510 mice compared with nontransgenic littermates. These observations were correlated with a progressive increase in locomotor activity. Indeed, no body weight difference was observed at 2 months when locomotor activity was the same for both genotypes, whereas a lower body weight at 7 months and 12 months of age was correlated with a hyperactive phenotype. Hyperactivity seemed to be related to the presence of hyperphosphorylated tau because no significant difference in locomotor activity was observed at 2 months, when no hyperphosphorylated tau was detectable, but was present at 7 and 12 months when there was significant tau pathology. This is consistent with results from a previous study of locomotor activity in Tg4510 mice where hyperactivity was attenuated by transgene suppression with doxycycline (Jul et al., 2015). However, the authors mentioned that activity was not normalized to nontransgenic levels, suggesting that factors other than tau accumulation could be...
involved. Although hyperactivity in Tg4510 was observed during both night and day, the ratio of night over day activity was maintained or exaggerated, indicating a sustained responsiveness to circadian cues unlike other mouse models of AD (Sterniczuk et al., 2010).

Classical literature using brain lesions identified the prefrontal cortical region as one that results in hyperactivity when damaged (Zubek and DeLorenzo, 1952), confirming earlier work in monkeys (Richter and Hines, 1938). Subsequent studies using lesions in rats identified the dorsal hippocampus as a specific region underlying persistent increases in exploratory behavior in rats (Kimble, 1963).

Confirming a role of the dorsal hippocampus in locomotor activity, MacLean (MacLean, 1957) found that stimulation of this structure arrested movements in freely behaving rats. Lesions in amygdala performed in the rat also showed a role for this structure in regulation of spontaneous locomotor activity (Korczynski and Fonberg, 1979). In the Tg4510 mouse model, there is accumulation of Gallyas positive tau inclusions and loss of neurons in all of these structures (Cook et al., 2014; Dickey et al., 2009; Santacruz et al., 2005). We have found 25% reductions in hippocampal volume and 30% losses of neurons in the hippocampus of Tg4510 animals at 7 months.

Fig. 6. Tau pathology in the hypothalamus over the course of aging. Micrographs representing staining of tau phosphorylated at Ser396 in nontransgenic littermates (A, C) and Tg4510 mice (B, D) at 7 (A, B), and 12 months of age (C, D) in coronal sections (25 μm thickness) using Mirax software (Zeiss Inc). The boxed area on the left panels of each pair is enlarged on the right. Cellular staining for phosphorylated tau is present in the hypothalamus.

Table 1

<table>
<thead>
<tr>
<th>Parameter</th>
<th>2 mo</th>
<th>7 mo</th>
<th>12 mo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ntg</td>
<td>Tg4510</td>
<td>Ntg</td>
</tr>
<tr>
<td>Diurnal locomotor activity (24 h counts × 10^4)</td>
<td>1.43 ± 0.18</td>
<td>1.65 ± 0.26</td>
<td>1.73 ± 0.24</td>
</tr>
<tr>
<td>Nocturnal locomotor activity (24 h counts × 10^4)</td>
<td>3.76 ± 036</td>
<td>6.84 ± 0.08</td>
<td>2.75 ± 0.26</td>
</tr>
<tr>
<td>Energy expenditure (kJ/d)</td>
<td>38.62 ± 2.14</td>
<td>33.66 ± 1.29</td>
<td>35.62 ± 1.07</td>
</tr>
<tr>
<td>RER (mL O₂/h)</td>
<td>0.87 ± 0.01</td>
<td>0.84 ± 0.01</td>
<td>0.83 ± 0.01</td>
</tr>
<tr>
<td>Resting metabolism</td>
<td>87.8 ± 0.8</td>
<td>72.7 ± 1.0</td>
<td>112.2 ± 1.4</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>20.3 ± 1.1</td>
<td>21.9 ± 0.9</td>
<td>31.6 ± 1.4</td>
</tr>
<tr>
<td>Brain weight (mg)</td>
<td>449.4 ± 11.3</td>
<td>436.3 ± 5.1</td>
<td>472.9 ± 17.1</td>
</tr>
<tr>
<td>Food intake (kcal/d)</td>
<td>424.7 ± 49.9</td>
<td>323.3 ± 44.3</td>
<td>336.4 ± 29.7</td>
</tr>
<tr>
<td>AEE (%)</td>
<td>73.0 ± 5.6</td>
<td>73.8 ± 3.4</td>
<td>69.9 ± 3.3</td>
</tr>
<tr>
<td>VAT (mg)</td>
<td>406 ± 78</td>
<td>451 ± 161</td>
<td>1412 ± 278</td>
</tr>
<tr>
<td>Plasma leptin (ng/mL)</td>
<td>1.72 ± 0.38</td>
<td>3.77 ± 2.11</td>
<td>9.31 ± 2.31</td>
</tr>
<tr>
<td>BAT (mg)</td>
<td>66.9 ± 9.1</td>
<td>95.2 ± 10.4</td>
<td>169 ± 20.3</td>
</tr>
<tr>
<td>UCPI (arbitrary units), ratio to actin</td>
<td>0.02 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>0.15 ± 0.02</td>
</tr>
<tr>
<td>PGC-1α (arbitrary units), ratio to actin</td>
<td>0.36 ± 0.05</td>
<td>0.49 ± 0.08</td>
<td>1.06 ± 0.11</td>
</tr>
</tbody>
</table>

Key: AEE, apparent energy absorption efficiency; BAT, brown adipose tissue; Ntg, Nontransgenic; PGC-1α, peroxisome proliferator-activated receptor γ coactivator 1-alpha; RER, respiratory exchange rate; UCPI-1, uncoupling protein 1; VAT, white adipose tissue.

* Significantly different from age-matched nontransgenic littermates.

† Significantly different from 7 month old Tg4510.

‡ Significantly different from 2 month old nontransgenic.
(Brownlow et al., 2014; Nash et al., 2013). Thus, one interpretation of the hyperactivity in our study suggests damage or injury to areas of the limbic system known to control locomotor activity.

Our results also show variations of DEE over the course of aging. DEE is the sum of multiple physiological processes including resting metabolism (i.e., minimum energy requirements for cell activity), the thermogenic effect of food (energy used for digestion), and locomotor activity; the last being considered as the largest contributor to individual differences (Lowell and Spiegelman, 2000). Notably in our study, group differences in DEE did not always associate with locomotor activity. Instead, energy expenditure correlated stronger to changes in RMR. We observed a switch to increased food intake and RMR in Tg4510 mice as the mice transitioned from the asymptomatic phase (2 months) when over-expression of tau has not yet led to pathological lesions, to the symptomatic phase where tau pathology is associated with tangles, brain atrophy, and cognitive impairments (7 months). The end stage of the tau phenotype (12 months) resulted in a reduction in RMR that was not observed in nontransgenic mice between 7 and 12 months of age. There was further a decline in DEE in 12-month-old Tg4510 mice relative to nontransgenic mice, in spite of retention of the elevated locomotor activity during the dark phase of the cycle. This was associated with a reduced RER, implying greater metabolism of fat relative to carbohydrate. Indeed, there was a specific loss of white adipose tissue mass in the transgenic mice, whereas muscle and brown fat mass remained similar to non-transgenic mice.

To maintain weight, increased energy utilization must be compensated for by an increase in energy intake. Therefore, the decrease in body weight in both tau mice models and AD patients should be compensated by an increased energy intake or by diminished energy expenditure. At a cellular level, the main mechanism involved in differences in metabolism is uncoupling and proton leak across the inner mitochondrial membrane which is under the control of carrier proteins (Dulloo and Samec, 2001) such as uncoupling protein-1 (UCP-1) in brown adipose tissue. In the conditions of our experiment, no differences were observed in the levels of PGC1-α and its target UCP-1 in brown adipose tissue, suggesting that this mechanism was not engaged. Nevertheless, 12-month-old mice seemed to trigger compensatory mechanisms such as decreasing RMR and using more energy efficient fuels, such as lipids, as suggested by the observed decrease in respiratory exchange ratio and fat pad loss. However, these mechanisms were not sufficient to overcome the reduced weight gain occurring at younger ages. Indeed, even though we observed an increase in food intake at 7 months, it was not sufficient to compensate for the hyperactivity and maintain body weight. We verified that this was not due to a defect in energy absorption as fecal energy content did not differ between transgenic and nontransgenic littermates at any of the ages tested. This argues that loss of brain integration of peripheral signals or a deregulation of orexigenic pathways was involved. Information regarding nutrient status and energy stores is communicated to the brain through diverse endocrine and afferent neural signals where it is subsequently integrated in the hypothalamus to modulate food behavior and energy expenditure to maintain body weight (Morton et al., 2006). Experiments performed 60 years ago showed that lesions of the ventromedial hypothalamus in the rat led to hyperphagia, decreased energy expenditure, and increased body weight gain, whereas lesions of the lateral hypothalamic area would result in decreased food intake (Anand and Brobeck, 1951). Hypothalamic lesions and volume loss is also reported in patients with AD and FTD and have been linked to disturbances in feeding behavior observed in these diseases (Piguet et al., 2011). In this study, we showed that Tg4510 mice are characterized by hyperphosphorylated tau in the hypothalamus at both 7 months and 12 months of age that may be linked to the variations observed in energy expenditure, food efficiency, and body weight. In addition, white adipose tissue and plasma leptin concentration were dramatically decreased in aging Tg4510 mice compared with nontransgenic littermates, which indicate either a deregulation of fat sensing (the also called “adipostat”) located in the hypothalamus (Kennedy, 1953), or a default in efferent response to the peripheral organs involved in energy storage such as liver and adipose tissue. Further analysis will be interesting to determine if specific areas or neuronal populations of the hypothalamus are differentially affected by tau pathology.

Recent literature (Ishii et al., 2014) showed that amyloid pre-cursor protein Tg2576 mice had hypothalamic leptin signaling dysfunction leading to early body weight deficits and increased energy expenditure without alterations in feeding behavior. These observations appeared correlated to poor function of the strong orexigenic effect of neuropeptide Y in the hypothalamus. The phenotype described in this study resembled our data and similar mechanisms might be involved in Tg4510 mice. In a different experiment, (Adebakin et al., 2012) reported that administration of an anorectic factor involved in meal termination, cholecystokinin, in 3XtgAD mice had no effect on food intake compared with non-transgenic controls. Detection of cholecystokinin by the brainstem appeared intact in these mice but efferent mechanisms might have been lost. In patients, some studies have also shown a reduction in content of the anorexigen neurotransmitter serotonin (5HT) in the brain of both AD and FTD patients (Huey et al., 2006), and a decrease in the density of some of its receptors (Cross et al., 1984; Tsang et al., 2010). In tau mice, a reduction in serotonergic neurones in THY-Tau22 mice was reported (Van der Jeugd et al., 2013). Serotonin is involved in mood, sleep, feeding, and energy balance (Lam and Heisler, 2007) and could be involved in the deregulation of homeostasis observed in both patients and mice models.

One advantage of longitudinal studies of this type is one can observe changes within the same mice circumventing cohort effects contributing to different outcomes at different ages. The differences seen in asymptomatic, symptomatic, and end stages of the tau phenotype may be the reason different studies sometimes report contradictory results in patients and mouse models. It is conceivable that changes in energy metabolism over the course of AD have a biphasic response of initially elevated metabolism followed by reduced metabolism as pathology becomes more severe, as seen in our Tg4510 mouse model of tauopathy. Changes in peripheral metabolism may be used as a noninvasive, potential clinical marker for the different stages of the disease, reflecting changes in the central nervous system.

Finally, part of the phenotype observed in this study, especially at 12 month old, resembled some symptoms observed in cachexia. Cachexia, also known as wasting syndrome, is often observed in patients with cancer and has been reported in patients with AD (Koopmans et al., 2007), being listed as the cause of death more often than dementia itself. The metabolic deregulation of cachexia leads to progressive weight loss and predicts both morbidity and mortality. It is feasible that cachexia-related metabolic disturbances could contribute to cognitive impairments in patients with AD, as in patients with cancer. Therefore, it remains important to determine how metabolism becomes dysregulated over time in AD. Understanding the mechanisms involved in such dysregulation over the course of dementia could lead to the development of effective interventions for ensuring metabolic homeostasis and may slow down the progression of the disease.
5. Conclusion

This is the first longitudinal study showing differences in metabolic rate, body weight, and body composition in a mouse model of tau pathology. These findings raise new questions about the role of tau in body weight loss and metabolic deregulation related to AD pathology especially regarding the hypothesis in which hypermetabolism is responsible for weight loss in AD patients. Indeed, we report that resting metabolism was differently affected with aging in a manner which correlates with the severity of pathology. However, the reduced weight gain observed in our study appears because of a progressive hyperactive phenotype plus increased metabolic rate that is not adequately compensated for by increased food intake in 7-month-old mice. Interestingly, body weight loss was associated with a dramatic reduction in white adipose tissue content, and a consequent decrease in plasma leptin concentration. As mice reach the end stage of the phenotype (average longevity is 14–15 months), hyperactivity is retained but is compensated by a reduced resting metabolic rate, despite a lower energy intake at 12 months of age.

Disclosure statement

There is no actual or potential conflict of interest.

Acknowledgements

This work was supported by Alzheimer’s Association grant IRG-10-174448 (D.M.), NIH grant NS076308 (D.M.), and Byrd Alzheimer’s Institute BRD 712. The authors thank the Comparative Medicine staff for their assistance in caring for the mice. The authors also thank John Kuhn, PhD, and Yolanda Daza, Department of Chemical & Biomedical Engineering, University of South Florida for use of the calorimeter.

References
